Actionnariat et activité des initiés pour Myriad Genetics, Inc. (MYGN): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $3.86 |
| Capitalisation | $365M |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-03 | Fox Jennifer Lynne | F-InKind | 4,398 | $14K |
| 2026-08-16 | Wheeler Benjamin Richard | F-InKind | 8,761 | $27K |
| 2026-06-23 | Skovronsky Daniel | |||
| 2026-06-11 | Raha Samraat S. | A-Award | 3,542 | $14K |
| 2026-06-11 | Donnelly Brian J | A-Award | 5,000 | $20K |
| 2026-06-08 | Kumar Rashmi | S-Sale | 15,000 | $67K |
| 2026-06-04 | Skovronsky Daniel | A-Award | 59,701 | |
| 2026-06-04 | Newcomer Lee Nisley | A-Award | 59,701 | |
| 2026-06-04 | Davis Mark Steven | A-Award | 59,701 | |
| 2026-06-04 | Phanstiel S. Louise | A-Award | 59,701 |
Bilan (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $102.4M | $110.9M | $93.2M | $163.7M | $117.0M | $257.4M | $56.9M | $132.1M | $102.4M | $149.6M |
| Placements à Court Terme | $48.3M | $69.7M | $43.7M | $54.1M | $33.7M | $81.4M | $58.0M | $8.8M | 0 | 0 |
| Créances | $95.9M | $103.3M | $138.6M | $71.0M | $89.5M | $91.3M | $101.6M | $114.3M | $121.2M | $115.3M |
| Stocks | $42.2M | $34.3M | $31.4M | $29.1M | $27.1M | $15.3M | $20.1M | $22.0M | $27.5M | $30.6M |
| Actifs Courants | $301.7M | $327.6M | $348.6M | $331.7M | $389.4M | $484.8M | $274.6M | $313.6M | $298.0M | $332.6M |
| Immobilisations Corporelles | $51.1M | $43.2M | $57.3M | $103.0M | $100.4M | $125.3M | $187.3M | $180.6M | $172.4M | $163.4M |
| Goodwill | $316.1M | $318.6M | $417.2M | $327.6M | $329.2M | $239.2M | $286.8M | $287.4M | $286.3M | $51.6M |
| Actifs Incorporels | $491.5M | $455.2M | $684.7M | $605.3M | $578.8M | $404.1M | $379.7M | $349.5M | $262.4M | $153.4M |
| Actifs Totaux | $1.21B | $1.18B | $1.56B | $1.40B | $1.42B | $1.32B | $1.20B | $1.15B | $1.03B | $706.6M |
| Dettes Fournisseurs | $22.0M | $26.0M | $33.3M | $21.7M | $20.5M | $29.6M | $28.8M | $25.8M | $32.3M | $30.0M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $217.5M | $102.2M | $117.8M | $147.0M | $145.9M | $204.3M | $137.2M | $155.9M | $164.1M | $133.8M |
| Dette à Long Terme | $99.1M | $9.3M | $233.5M | $224.4M | $224.8M | 0 | 0 | $38.5M | $39.6M | $119.9M |
| Passifs Totaux | $440.9M | $209.2M | $473.8M | $486.4M | $537.8M | $352.9M | $312.9M | $363.3M | $326.5M | $338.6M |
| Réserves | -$78.2M | $54.1M | $25.6M | -$173.9M | -$227.0M | -$254.2M | -$366.2M | -$629.5M | -$756.8M | -$1.12B |
| Capitaux Propres | $768.4M | $966.1M | $1.09B | $918.2M | $881.0M | $967.8M | $885.8M | $783.2M | $701.1M | $368.0M |
| Dette Totale | $99.1M | $9.3M | $233.5M | $294.8M | $289.0M | $92.3M | $145.0M | $152.1M | $140.3M | $209.8M |
| Dette Nette | -$51.6M | -$171.3M | $96.6M | $77.0M | $138.3M | -$246.5M | $30.1M | $11.2M | $37.9M | $60.2M |
| Fonds de Roulement | $84.2M | $225.4M | $230.8M | $184.7M | $243.5M | $280.5M | $137.4M | $157.7M | $133.9M | $198.8M |
Santé financière
| Dette / Capitaux propres | 0.69 |
| Ratio de liquidité | 2.21 |
Rentabilité
| Rentabilité des capitaux propres | -32.59% |
| Rentabilité du capital investi | -19.13% |
| Rentabilité des actifs | -17.62% |
| Marge brute | 68.83% |
| Marge opérationnelle | -12.22% |
| Marge nette | -13.96% |
Entreprises liées: AMN · CDNA · CSTL · DNA · DRIO · EVH · FLGT
Explorer le secteur: Healthcare · Medical - Diagnostics & Research
Plus de sections de MYGN: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions